Publication | Open Access
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
172
Citations
14
References
2013
Year
OncologyMelanomaClinical TrialsMetastatic MelanomaImmune Checkpoint InhibitorCancer TreatmentFour-year Survival RatesMedicineRadiation OncologyHealth Sciences
| Year | Citations | |
|---|---|---|
Page 1
Page 1